Grupo de investigación de biomarcadores en cáncer (GReBiC)
- Número de publicaciones
- 520
Publicaciones
-
Mateo, F; Arenas, EJ; Aguilar, H; Serra-Musach, J; de Garibay, GR; Boni, J; Maicas, M; Du, S; Iorio, F; Herranz-Ors, C; Islam, A; Prado, X; Llorente, A; Petit, A; Vidal, A; Catala, I; Soler, T; Venturas, G; Rojo-Sebastian, A; Serra, H; Cuadras, D; Blanco, I; Lozano, J; Canals, F; Sieuwerts, AM; de Weerd, V; Look, MP; Puertas, S; Garcia, N; Perkins, AS; Bonifaci, N; Skowron, M; Gomez-Baldo, L; Hernandez, V; Martinez-Aranda, A; Martinez-Iniesta, M; Serrat, X; Ceron, J; Brunet, J; Barretina, MP; Gil, M; Falo, C; Fernandez, A; Morilla, I; Pernas, S; Pla, MJ; Andreu, X; Segui, MA; Ballester, R; Castella, E; Nellist, M; Morales, S; Valls, J; Velasco, A; Matias-Guiu, X; Figueras, A; Sanchez-Mut, JV; Sanchez-Cespedes, M; Cordero, A; Gomez-Miragaya, J; Palomero, L; Gomez, A; Gajewski, TF; Cohen, EEW; Jesiotr, M; Bodnar, L; Quintela-Fandino, M; Lopez-Bigas, N; Valdes-Mas, R; Puente, XS; Viñals F; Casanovas, O; Graupera, M; Hernandez-Losa, J; Ramón Y Cajal S; Garcia-Alonso, L; Saez-Rodriguez, J; Esteller, M; Sierra, A; Martin-Martin, N; Matheu, A; Carracedo, A; Gonzalez-Suarez, E; Nanjundan, M; Cortes, J; Lazaro, C; Odero, MD; Martens, JWM; Moreno-Bueno, G; Barcellos-Hoff, MH; Villanueva, A; Gomis, RR; Pujana, MA
Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition
ONCOGENE 36 2737-2749. .
-
Lange, B; Khan, P; Kalmambetova, G; Al-Darraji, HA; Alland, D; Antonenka, U; Brown, T; Balcells, ME; Blakemore, R; Denkinger, CM; Dheda, K; Hoffmann, H; Kadyrov, A; Lemaitre, N; Miller, MB; Nikolayevskyy, V; Ntinginya, EN; Ozkutuk, N; Palacios, JJ; Popowitch, EB; Porcel, JM; Teo, J; Theron, G; Kranzer, K
Diagnostic accuracy of the Xpert (R) MTB/RIF cycle threshold level to predict smear positivity: a meta-analysis
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE 21 493-502. .
-
Porcel, JM; Lui, MMS; Lerner, AD; Davies, HE; Feller-Kopman, D; Lee, YCG
Comparing approaches to the management of malignant pleural effusions
Expert Review of Respiratory Medicine 11 273-284. .
-
Llombart-Cussac, A; Cortes, J; Pare, L; Galvan, P; Bermejo, B; Martinez, N; Vidal, M; Pernas, S; Lopez, R; Muñoz M; Nuciforo, P; Morales, S; Oliveira, M; de la Peña L; Pelaez, A; Prat, A
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
LANCET ONCOLOGY 18 545-554. .
-
Porcel, JM
Diagnostic usefulness of pleural fluid total leukocyte count and differential
REVISTA CLINICA ESPANOLA 217 149-150. .
-
Porcel, JM; Quiros, M; Gatius, S; Bielsa, S
Examination of cytological smears and cell blocks of pleural fluid: Complementary diagnostic value for malignant effusions
REVISTA CLINICA ESPANOLA 217 144-148. .
-
Irigoyen A; Gallego J; Guillén Ponce C; Vera R; Iranzo V; Ales I; Arévalo S; Pisa A; Martín M; Salud A; Falcó E; Sáenz A; Manzano Mozo JL; Pulido G; Martínez Galán J; Pazo-Cid R; Rivera F; García García T; Serra O; Fernández Parra EM; Hurtado A; Gómez Reina MJ; López Gomez LJ; Martínez Ortega E; Benavides M; Aranda E
Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group
EUROPEAN JOURNAL OF CANCER 75 73-82. .
-
Fernandez-Martinez, A; Pascual, T; Perrone, G; Morales, S; de la Haba, J; Gonzalez-Rivera, M; Galvan, P; Zalfa, F; Amato, M; Gonzalez, L; Prats, M; Rojo, F; Manso, L; Pare, L; Alonso, I; Albanell, J; Vivancos, A; Gonzalez, A; Matito, J; Gonzalez, S; Fernandez, P; Adamo, B; Muñoz M; Viladot, M; Font, C; Aya, F; Vidal, M; Caballero, R; Carrasco, E; Altomare, V; Tonini, G; Prat, A; Martin, M
Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer
Oncotarget 8 21930-21937. .
-
Gasol Cudos, A.; Morales Murillo, S.; Panades Siurana, M. J.; Vilardell Villellas, F.; Canosa Morales, C.; Mele Olive, J.; Iglesias Martinez, E.; Salud Salvia, A.
Change in treatment decisions according to Oncotype Dx Recurrence Score in node positive and negative, estrogen-receptor positive (ER+), HER2 negative breast cancer in a single institution
BREAST 32 92-93. .
-
Gavila, J.; Perez-Garcia, J.; Calvo, I.; Ciruelos, E.; Munoz, M.; Virizuela, J. A.; Ruiz, I.; Andres, R.; Morales, S.; Perello, A.; Sanchez, P.; Garcia-Saenz, J. A.; Quero Guillen, J. C.; Gonzalez-Santiago, S.; Garau Llinas, I.; Gonzalez-Martin, A.; Sanchez de Ibarguen, B. Cantos; Zaragoza, K.; de la Pena, L.; Llombart-Cussac, A.; Oliveira, M.
Neoadjuvant non-pegylated liposomal doxorubicin plus paclitaxel, trastuzumab and pertuzumab in patients with HER2+breast cancer - Final results of the SOLTI OPTI-HER HEART study
CANCER RESEARCH 77 -. .
-
Martin, M; Kahan, Z; Carrasco, E; Bartlett, CH; Casas, M; Gil-Gil, M; Munoz, M; Ciruelos, EM; Ruiz-Borrego, M; Margeli, M; Anton, A; Bermejo, B; Morales, S; Gal-Yam, E; Koehler, M; Garcia-Saenz, JA; de la Haba, J; Chacon, I; Zielinski, C
Phase III study of palbociclib (PD-0332991) in combination with endocrine therapy (exemestane or fulvestrant) versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with resistance to aromatase inhibitors. "The PEARL study" (GEICAM/2013-02)
CANCER RESEARCH 77 -. .
-
Aparicio, AP; Castan, JC; Pare, L; Galvan, P; Bermejo, B; Martinez, N; Vidal, M; Pernas, S; Lopez, R; Munoz, M; Nuciforo, P; Fasani, R; Morales, S; Oliveira, M; de la Pena, L; Pelaez, A; Llombart, A
PAM50 intrinsic subtype as a predictor of pathological complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer: First results of the PAMELA clinical trial
CANCER RESEARCH 77 -. .
